B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

SMN2

MOLECULAR TARGET

survival of motor neuron 2, centromeric

UniProt: Q16637NCBI Gene: 660718 compounds

SMN2 (survival of motor neuron 2, centromeric) is targeted by 18 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting SMN2

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Leflunomide1.956
2Pueraria1.393
3Genistein1.393
4Resveratrol1.393
5Mycophenolic Acid Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of1.393
6pd980591.393
7Thiabendazole 2-Substituted benzimidazole first introduced in 1962. It is active against1.393
8Apigenin 5,7,4'-trihydroxy-flavone,1.102
9Bromodeoxyuridine1.102
10kenpaullone1.102
11Niclosamide1.102
12trichostatic acid [Supplementary Concept] related to trichostatin1.102
13chrysin0.691
14Luteolin 5,7,3',4'-tetrahydroxy-flavone,0.691
15Azauridine0.691
16Lovastatin0.691
17piceatannol0.691
18tyrphostin ag 12950.691

About SMN2 as a Drug Target

SMN2 (survival of motor neuron 2, centromeric) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 18 compounds with documented SMN2 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

SMN2 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.